Insmed Inc., a global biopharmaceutical company dedicated to developing therapies for serious diseases, has announced a proposed public offering of $650 million in common stock. The offering is structured as an underwritten public offering, and Insmed plans to grant underwriters a 30-day option to purchase an additional $97.5 million in shares. This initiative is being managed by Goldman Sachs & Co. LLC and Leerink Partners as joint book-running managers. The completion and terms of the offering are subject to market conditions, and there is no guarantee regarding the finalization or the specifics of the offering.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。